Article | October 18, 2017

Tufts Study Uncovers The Economic Advantage Of Single-Source Drug Development And Manufacturing

Source: Patheon, part of Thermo Fisher Scientific
drug and healthcare cost

With patient care at the forefront, it is critical to assess the economics of both outsourcing models and ensure the one you select provides the most efficient path to commercialization. This was the purpose of a recent study by the Tufts Center for the Study of Drug Development (CSDD), which compared cycle times and development economics between multi- and single-source CDMO models.

Patheon, part of Thermo Fisher Scientific